The FDA has ordered BioNTech to immediately halt its Phase I/II trial of malaria vaccine candidate BNT165e, pending changes.
FP008 is designed for patients with solid tumors that have not responded to existing immunotherapies targeting PD-1.
The investigational new drug application for Zabalafin Hydrogel for the treatment of mild to moderate atopic dermatitis has ...
NEW YORK, March 04, 2025) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully hu ...
The FDA’s clinical hold has prompted a cautious response from investors, reflecting the heightened regulatory scrutiny that BioNTech now faces. The company’s immediate focus will be on resolving the ...
The FDA approved the investigational new drug application for a phase 1 trial of ADCE-T02 in advanced solid tumors.
Discover 7 biotech companies in Taiwan, a rising regional player in precision medicine, immunotherapy, and drug development!
Gireesh Babu, New Delhi Wednesday, March 5, 2025, 14:45 Hrs [IST] With the registration of clinical research organisations (CROs) to b ...
Strategic collaboration harnesses GATC's proprietary Artificial Intelligence-powered, validated Multiomics Advanced Technologyâ„¢ platform to rapidly optimize and derisk drug discovery and development, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results